One of the researchers, Professor Peter Bremner from St John of God Murdoch Hospital, says the aim of the research was to improve the health outcomes for patients, whilst also minimizing side effects.
“We set out to find the best way to relieve symptoms and prevent the progression of the disease,” Professor Bremner says.
“Through a randomised trial, we found triple therapy using glycopyrronium plus salmeterol/fluticasone propionate is clinically superior to salmeterol/ fluticasone alone.”
“We are really excited about this discovery as it will work towards improving the quality of life of those who struggle with COPD on a daily basis.”
The study is a collaboration between the seven research facilities across Australia and New Zealand.
Peter A Frith et al. Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study — a randomised controlled trial. Thorax 2015;0:1-9.